AR123998A1 - Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden - Google Patents

Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden

Info

Publication number
AR123998A1
AR123998A1 ARP210103065A ARP210103065A AR123998A1 AR 123998 A1 AR123998 A1 AR 123998A1 AR P210103065 A ARP210103065 A AR P210103065A AR P210103065 A ARP210103065 A AR P210103065A AR 123998 A1 AR123998 A1 AR 123998A1
Authority
AR
Argentina
Prior art keywords
segment
protein
chimeric protein
receptor
coronavirus
Prior art date
Application number
ARP210103065A
Other languages
English (en)
Spanish (es)
Inventor
Santiago Glay Chinea
Dunn Alejandro Miguel Martn
Roche Diamil Gonzlez
Fernndez Miladys Limonta
Prez Enrique Iglesias
Romero Mnica Bequet
Milin Hctor Santana
Perera Gabriel J Marquez
Lasa Alexis Musacchio
Rico Ania Cabrales
Nieto Gerardo Enrique Guillen
Vila Marta Ayala
Vazquez Eulogio Pimentel
Dorantes Gertrudis Rojas
Galindo Vivian Huerta
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Publication of AR123998A1 publication Critical patent/AR123998A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6075Viral proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/20Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/20011Coronaviridae
    • C12N2770/20071Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP210103065A 2020-11-04 2021-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden AR123998A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000081A CU24665B1 (es) 2020-11-04 2020-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden

Publications (1)

Publication Number Publication Date
AR123998A1 true AR123998A1 (es) 2023-02-01

Family

ID=79164940

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103065A AR123998A1 (es) 2020-11-04 2021-11-04 Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden

Country Status (12)

Country Link
US (1) US20230405106A1 (https=)
EP (1) EP4242222A1 (https=)
JP (1) JP2023548205A (https=)
CN (1) CN116802194A (https=)
AR (1) AR123998A1 (https=)
AU (1) AU2021373188A1 (https=)
CA (1) CA3197024A1 (https=)
CO (1) CO2023004963A2 (https=)
CU (1) CU24665B1 (https=)
MX (1) MX2023005211A (https=)
WO (1) WO2022096039A1 (https=)
ZA (1) ZA202304779B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025519107A (ja) * 2022-05-23 2025-06-24 バクスディグム カンパニー,リミティド ウイルスヌクレオカプシドを用いた結晶性タンパク質ベースの標的タンパク質融合自己組織化ナノ粒子製造プラットフォーム
WO2023229330A1 (ko) * 2022-05-23 2023-11-30 주식회사 백스다임 바이러스 뉴클레오캡시드를 이용한 오량체형 독소 단백질 기반 목적 단백질 융합 오량체 제조 플랫폼

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111217918B (zh) * 2020-03-04 2020-11-10 中山大学 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗
CN111366734B (zh) * 2020-03-20 2021-07-13 广州市康润生物科技有限公司 双指标筛选新冠病毒及预判重型肺炎的方法
CN111620952A (zh) * 2020-06-17 2020-09-04 苏州米迪生物技术有限公司 基于嵌合型病毒样颗粒的新型冠状病毒疫苗
CN111676248A (zh) * 2020-07-02 2020-09-18 军事科学院军事医学研究院军事兽医研究所 表达新型冠状病毒S基因与流感M1基因嵌合SARS-CoV-2 VLP的构建

Also Published As

Publication number Publication date
CA3197024A1 (en) 2022-05-12
CU24665B1 (es) 2023-06-13
US20230405106A1 (en) 2023-12-21
MX2023005211A (es) 2023-05-16
EP4242222A1 (en) 2023-09-13
JP2023548205A (ja) 2023-11-15
AU2021373188A1 (en) 2023-06-01
CO2023004963A2 (es) 2023-06-20
WO2022096039A1 (es) 2022-05-12
AU2021373188A9 (en) 2024-10-10
CN116802194A (zh) 2023-09-22
ZA202304779B (en) 2024-09-25
CU20200081A7 (es) 2022-06-06

Similar Documents

Publication Publication Date Title
CL2022003733A1 (es) Análogos de nucleósido de 1’-ciano y usos de los mismos
BR112022024248A2 (pt) Vacinas de combinação à base de ácido nucleico
CL2022000587A1 (es) Profármacos antivirales y formulaciones de los mismos
CR8935A (es) Inhibidores de la arn polimerasa dependiente del arn del virus de la hepatitis c y composiciones
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
EA201100927A1 (ru) Циклические аналоги 4-амино-4-оксобутаноил-пептидов, ингибиторы репликации вирусов
ECSP22076862A (es) Compuestos antivirales y métodos para la administración de los mismos
UY38483A (es) Heterociclos funcionalizados como agentes antivirales
UY37998A (es) Agentes antivirales contra la hepatitis b
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
AR123998A1 (es) Proteína quimérica que comprende el dominio de unión al receptor de la proteína de la espiga de coronavirus y composiciones que las comprenden
PE20181176A1 (es) Composiciones biofarmaceuticas
FI3534939T3 (fi) Rokote sian parvovirusta ja sian hedelmättömyyttä ja respiratorista oireyhtymää aiheuttamaa virusta vastaan ja menetelmän sen valmistamiseksi
MX2019003116A (es) Nueva vacuna contra la gripe porcina.
MX2021004907A (es) Vacuna de ibv 4/91 con proteina espicular heterologa.
UY38383A (es) Heterociclos funcionalizados como agentes antivirales
BR112023000220A2 (pt) Formulações de longa ação
BR112018015629A2 (pt) ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla?
CL2020001884A1 (es) Anticuerpos humanos para la hemaglutinina de influenza.
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
MX2025013861A (es) Compuestos anti virus de la inmunodeficiencia humana (vih)
AR133423A1 (es) Vacuna ibv con proteína de espícula dmv/1639 heteróloga
CO2022005281A2 (es) Anticuerpos antihemaglutinina y métodos de uso de estos
CU20200110A7 (es) Péptidos para el tratamiento de infecciones respiratorias de origen viral